Drug Trial Radar · NCT01710826
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Mar 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Oct 2012
Primary completion
Feb 2013
Study completion Feb 2013
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 19, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To assess in healthy adult subjects: * The tolerability and safety of ascending repeated oral doses of Genz-682452. * The pharmacokinetic parameters of Genz-682452 after ascending repeated oral doses. * The pharmacodynamics of Genz-682452 after ascending repeated oral doses.
Conditions
- Healthy
Interventions
Genz-682452Biological
Capsules for oral administration.
PlaceboBiological
Placebo capsules matching the Genz-682452 capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 through Day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.